Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

116
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
116
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

149
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
149
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

122
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
122
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

145
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
145
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

84
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
84
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.5K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab, Acalabrutinib, and Durvalumab for Primary Central Nervous System Lymphoma: A Single-arm, Phase 1b, Multi-center Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Isolation of C-29 oxygenated oleanane triterpenoids and a (+)-muurolene type sesquiterpenoid from the fruiting bodies of Fuscoporia torulosa and their bioactivities.

Journal of natural medicines·2024
Same author

Bayesian hierarchical models for adaptive basket trial designs.

Pharmaceutical statistics·2023
Same author

Recalibrating Risk Prediction Models by Synthesizing Data Sources: Adapting the Lung Cancer PLCO Model for Taiwan.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2022
Same author

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

Use of likelihood estimates for variances for the design and evaluation of multiregional clinical trials with heterogeneous variances.

Statistics in medicine·2021

Related Experiment Video

Updated: Dec 13, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.1K

Use of tolerance intervals for assessing biosimilarity.

Chian Chen1, Chin-Fu Hsiao1

  • 1Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan.

Statistics in Medicine
|August 6, 2020
PubMed
Summary

Assessing biosimilarity requires evaluating variability, not just mean differences. Tolerance intervals offer a more stringent method by considering entire clinical outcome populations for accurate comparisons.

Keywords:
biosimilarintersection-union testquantiletolerance interval

More Related Videos

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.1K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.3K

Related Experiment Videos

Last Updated: Dec 13, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.1K
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
08:54

Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples

Published on: May 19, 2020

8.1K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.3K

Area of Science:

  • Pharmacology
  • Biostatistics

Background:

  • Biosimilars are biological products highly similar to reference drugs, with no clinically meaningful differences.
  • Manufacturing processes for biosimilars can introduce variations due to their biological origin.
  • Current biosimilarity assessments may overlook critical variability data by focusing solely on mean differences.

Purpose of the Study:

  • To propose a novel statistical approach for assessing biosimilarity.
  • To emphasize the importance of considering population variability in biosimilar comparisons.
  • To introduce tolerance intervals as a more stringent method for biosimilarity evaluation.

Main Methods:

  • Utilizing tolerance intervals and associated hypothesis testing for biosimilarity assessment.
  • Accounting for the entire population of clinical outcomes for both test and reference products.
  • Illustrating the proposed method with a real-world example.

Main Results:

  • The proposed tolerance interval approach provides a more stringent assessment than confidence intervals.
  • This method is particularly effective when mean differences are small but variability differs.
  • It ensures a comprehensive evaluation of clinical outcome populations.

Conclusions:

  • Tolerance intervals offer a robust framework for evaluating biosimilarity by incorporating variability.
  • This approach enhances the rigor of biosimilar comparisons, especially in sensitive cases.
  • The method ensures that biosimilars are truly comparable to reference products across their entire outcome distributions.